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The Nrf2 pathway is frequently activated in human
cancers through mutations in Nrf2 or its negative
regulator KEAP1. Using a cell-line-derived gene
signature for Nrf2 pathway activation, we found that
some tumors show high Nrf2 activity in the absence
of known mutations in the pathway. An analysis of
splice variants in oncogenes revealed that such
tumors express abnormal transcript variants from
the NFE2L2 gene (encoding Nrf2) that lack exon 2,
or exons 2 and 3, and encode Nrf2 protein isoforms
missing the KEAP1 interaction domain. The Nrf2
alterations result in the loss of interaction with
KEAP1, Nrf2 stabilization, induction of a Nrf2 tran-
scriptional response, andNrf2 pathway dependence.
In all analyzed cases, transcript variants were the
result of heterozygous genomic microdeletions.
Thus, we identify an alternative mechanism for Nrf2
pathway activation in human tumors and elucidate
its functional consequences.INTRODUCTION
Lung cancer is the primary cause of cancer-related death for
men and women in the United States. The majority of lung can-
cers are non-small-cell lung cancers (NSCLCs), and most of
these belong to either adenomatous or squamous subtypes.
Recent studies have identified the genomic alterations that
underlie these tumors, showing distinct patterns of mutational
processes (Cancer Genome Atlas Research Network, 2012,
2014; Imielinski et al., 2012). While both subtypes show a high
frequency of TP53 and NF1 mutations, KRAS and EGFR muta-Cell Re
This is an open access article under the CC BY-Ntions are more common in adenomatous tumors, whereas
PIK3CA mutations are more prevalent in squamous tumors.
Adenomatous and squamous lung tumors additionally show
recurrent mutations in KEAP1, an adaptor protein that recruits
the Cul3 ubiquitin ligase to the transcription factor Nrf2 (encoded
by the NFE2L2 gene). In addition, Nrf2 is frequently mutated in
squamous tumors (Shibata et al., 2008). Both of these alterations
cause loss of Nrf2 ubiquitination and stabilization of the protein,
resulting in high-level transcription of Nrf2 target genes (Leino-
nen et al., 2014).
KEAP1/Nrf2 represents one of the most important cellular
pathways for sensing and responding to increases in oxidative
stress. Under normal conditions, Nrf2 is constitutively targeted
for ubiquitination by KEAP1, mediated through N-terminal DLG
(low-affinity) and ETGE (high-affinity) interaction motifs that
bind a KEAP1 dimer (McMahon et al., 2006; Tong et al.,
2006a). When oxidative stress or electrophile levels increase,
key cysteine residues in KEAP1 become oxidized, decreasing
the ability of KEAP1 to cause Nrf2 ubiquitination (Tong et al.,
2006b). Nrf2 target genes are situated downstream of defined
antioxidant response elements (AREs), which restore cellular
homeostasis by increasing cellular reducing power through in-
creases in glutathione levels, NADPH levels, and upregulation
of drug transporters (Hirotsu et al., 2012). Tumor-associated
mutations in NFE2L2 and KEAP1 thereby hijack a highly regu-
lated cellular process that provides a selective advantage for
the affected cells in a manner that is not completely understood.
In this study, we identify tumor-specific alterations that have
been missed by conventional sequencing and copy number ap-
proaches. Using publicly available RNA sequencing (RNA-seq)
data from The Cancer Genome Atlas (TCGA) project, we identify
recurrent transcript variants in key oncogenes that are not de-
tected in normal tissue samples. One of the top hits from this
analysis is NFE2L2, with alterations seen in squamous NSCLC
and head and neck squamous carcinoma (HNSC). We exploreports 16, 2605–2617, September 6, 2016 ª 2016 Genentech. 2605
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the mechanisms underlying these alterations and their conse-
quences on Nrf2 activity and function.
RESULTS
Identification of NSCLC Cell Lines with Mutations in
KEAP1 or NFE2L2
We documented the status of KEAP1 and NFE2L2 in a panel of
113 NSCLC cell lines profiled by RNA-seq, exome sequencing
(exome-seq), or SNP arrays to identify mutations, copy-num-
ber changes, and loss of heterozygosity (LOH) of these genes
(Figure S1A; Table S1). KEAP1 mutations were found in 29/113
cell lines (26%), and NFE2L2 mutations were detected in 4/113
cell lines (4%). With the exception of NCI-H661, all KEAP1
mutant cell lines showed homozygous expression of the mutant
allele, which was associated with copy-neutral LOH. In contrast,
the NFE2L2 mutations were heterozygous and not associated
with LOH. A further two cell lines (HCC1534 and NCI-H1437)
showed no detectable KEAP1 mRNA, due to bi-allelic loss of
the KEAP1 gene. The Nrf2 mutations were in the previously iden-
tified hotspots in the KEAP1 interface regions (Figure S1B) (Shi-
bata et al., 2008) and comprised point mutations and an in-frame
three-amino-acid deletion. The mutations in KEAP1 were spread
throughout the primary sequence (Figure S1C), with few obvious
hotspots. However, when mapped onto the KEAP1/Nrf2 peptide
crystal structure (Fukutomi et al., 2014), the mutations clustered
in the loops extending from the KEAP1 core beta propeller close
to the interaction site with Nrf2 (Figure S1D).
Identification of a Mutant KEAP1 Gene Signature
To determine the transcriptional consequences of KEAP1
mutations in NSCLC cell lines, we asked which genes were
significantly differentially expressed (adjusted p < 0.01, absolute
mean log2 fold change > 1) in the KEAP1 mutant compared to
wild-type cell lines. Overall, 27 genes were significantly upre-
gulated in the KEAP1mutant cell lines (Figure 1A; Figure S1E; Ta-
ble S2), many of which have previously been identified as Nrf2
target genes from chromatin immunoprecipitation sequencing
(ChIP-seq), RNA-seq, or microarray studies (Chorley et al.,
2012; Hirotsu et al., 2012; MacLeod et al., 2009; Malhotra
et al., 2010). Only one gene was identified as significantly down-
regulated using these cutoffs (HSPB1). The protein targets of
these genes were also increased in KEAP1 mutant cell lines
compared to wild-type (Figure S1F).
Hierarchical clustering of 230 TCGA lung adenocarcinomas
based on the expression of these 27 genes resulted in the division
of twomajor groups (Figure 1B).Onegroupwasmainly character-
ized by high expression of the 27 signature genes and contained
43 tumors, out of which 32 (74%) were KEAP1 mutant. The other
group, characterized by low expression, contained 187 tumors,
out of which 179 (96%) were KEAP1 wild-type. When using
the same gene set to cluster TCGA lung squamous cell carci-
nomas, Nrf2 and KEAP1 mutant tumors were distinguished from
the Nrf2/KEAP1 wild-type tumors (Figure 1C), suggesting that
Nrf2 mediates most of the transcriptional consequences of
KEAP1 loss/mutation. Interestingly, therewere several squamous
NSCLC tumors that showed high expression of the 27 signature
genes without any known mutations in either KEAP1 or Nrf2.2606 Cell Reports 16, 2605–2617, September 6, 2016Identification of Abnormal NFE2L2 Transcript Variants
in Tumor Samples
We asked whether Nrf2 pathway activation in these tumors
might be driven by transcript alterations not recognized by
whole-exome-seq. To address this question, we performed de
novo prediction of splice variants from RNA-seq data and iden-
tified transcript variants in known oncogenes that are recurrently
observed in TCGA cancer samples but are rarely seen in normal
samples from the genotype-tissue expression (GTEx) project
(see Experimental Procedures). We included 19 cancer types
with at least 100 patients (6,359 samples in total). In 54 analyzed
oncogenes, we identified nine recurrent candidate cancer-
specific splice variants (>1% and n R 3 for a given cancer
type) (Table S3). Using the same detection criteria as in cancer
samples, none of these variants could be detected in normal
controls (2,958 samples in total). Grouping together related
variants with shared splice sites yielded five independent
alterations in four oncogenes (Figure 2A). These alterations
included several well-documented oncogenic transcript vari-
ants, including EGFRvIII in brain cancers (Cho et al., 2011),
MET exon 14 skipping in lung adenocarcinoma (Kong-Beltran
et al., 2006), andCTNNB1 exon 3 deletions in colorectal cancers
(Iwao et al., 1998). Interestingly, we also observed previously
uncharacterized splice variants in NFE2L2, which occurred in
patients with squamous NSCLC (3.3%; 16/481) and at lower
prevalence in patients with HNSC (1.5%; 6/403) (Figure 2A). A
more detailed analysis of NFE2L2 splice variants in lung squa-
mous cell carcinoma revealed two splice variants co-occurring
in the same patients, corresponding to a skip of NFE2L2 exon
2 in mRNAs transcribed from either one of two alternative pro-
moters (2.1%; 10/481) (Figure 2B). Two additional splice variants
co-occurred in a distinct set of patients (1.2%; 6/481), corre-
sponding to a skip ofNFE2L2 exons 2 and 3 (exon 2+3) inmRNAs
with either one of the two alternative transcript starts (Figure 2B).
All patients expressing NFE2L2 splice variants lacking exon 2
or exon 2+3 also showed expression of normal NFE2L2 tran-
scripts as evidenced by split reads supporting inclusion of exon
2. Both exons 2 and 3 are part of the NFE2L2 coding sequence.
For transcripts transcribed from the distal promoter, skip of
exon 2 or exon 2+3was predicted to result in an in-frame deletion
(p.D16_Q104del or p.D16_E134del for NP_006155) (Figure S2).
Transcripts for the proximal promoter have a start codon in exon
2. In this case, the skip of exon 2 or exon 2+3 was predicted to
cause translation from downstream internal start codons, result-
ing in an N-terminal truncation (p.M1_C103del or p.M1_G163del
for NP_001138884). The recurrence of NFE2L2 transcripts lack-
ing exon 2 and preservation of coding potential suggest that
these splice variantsmay present gain-of-function events confer-
ring a selective advantage. This is supported by the finding that
exon 2 encodes the Neh2 domain, containing the DLG and
ETGE motifs, which allow for interaction with KEAP1 (Itoh et al.,
1999) and which are mutated in 15% of squamous lung cancers
(Cancer Genome Atlas Research Network, 2012).
NFE2L2 Exon 2 Deletion Is Associated with Nrf2 Target
Gene Expression in Tumors
To assess whether the observed NFE2L2 transcript variants can
account for Nrf2 pathway activation in patients without known
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Figure 1. A Cell-Line-Derived Mutant KEAP1 Gene Signature Classifies Human Lung Tumors
(A) Volcano plot of log2 fold changes and adjusted p values for differential expression analysis between mutant (n = 25) and wild-type (n = 74) KEAP1 NSCLC cell
lines. Significantly differentially expressed genes (absolute log2 fold change > 1; adjusted p < 0.01) are indicated.
(B) Using unsupervised ward clustering, the KEAP1 gene signature classifies 32 (80%) of the 40 KEAP1mutant lung adenocarcinomas from TCGA. The mutation
status for selected genes is indicated indicated for each sample.
(C) The KEAP1 gene signature classifies 19 (86%) of 22 KEAP1 mutant and 27 (100%) of 27 NFE2L2 mutant lung squamous cell carcinomas from TCGA.
See also Figure S1 and Tables S1 and S2.mutations in KEAP1 or NFE2L2, we analyzed the co-occurrence
of NFE2L2 transcript variants and Nrf2 pathway mutations. In
the TCGA collection, 178 of the squamous lung tumors with
RNA-seq data were also profiled by exome-seq. In this subset,
ten tumors (6%) displaying the exon 2 or exon 2+3 deletion
were mutually exclusive with 48 tumors (27%) showing muta-
tions in either NFE2L2 or KEAP1 (Figure 2C). Moreover, all
exon-2-deleted tumors showed high expression of the 27 candi-
date Nrf2 target genes (Figure 2D). Similar observations were
made for 275 TCGA head and neck cancers, where NFE2L2exon deletions in five tumors (2%) were mutually exclusive with
mutations in NFE2L2 or KEAP1 in 26 tumors (9%) (Figures 2E
and 2F). These results suggest that the deletion of exon 2 repre-
sents an alternative mechanism for activation of Nrf2 in a subset
of squamous NSCLC and head and neck cancers.
Validation of NFE2L2 Transcript Variants in Cell Lines
To identify cell line models for further study, we analyzed RNA-
seq data from a large panel of human cancer cell lines (described
in Klijn et al., 2015; unpublished data) and searched for evidenceCell Reports 16, 2605–2617, September 6, 2016 2607
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Figure 2. NFE2L2 Transcript Variants Lacking Exon 2 Are Observed in Lung and in Head and Neck Squamous Cell Carcinoma
(A) Heatmap of frequency of recurrent transcript alterations in 19 cancer types. GBM, glioblastoma; LUSC, lung squamous cell carcinoma; LGG, lower grade
glioma; LUAD, lung adenocarcinoma; CRC, colorectal cancer; HNSC, head and neck squamous cell carcinoma; STAD, stomach adenocarcinoma; BLCA,
bladder urothelial carcinoma; BRCA, breast cancer; CESC, cervical cancer; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma;
LAML, acute myeloid leukemia; LIHC, liver hepatocellular carcinoma; OV, ovarian carcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous mela-
noma; THCA, thyroid carcinoma; UCEC, endometrial carcinoma.
(B)NFE2L2 exons and splice junctions predicted from RNA-seq data. Two annotated transcripts are shown in gray. Identified junctions corresponding to the skip
of exon 2 (J2, J5) or exon 2+3 (J3, J6) are shown in red and blue, respectively. Heatmap illustrating read evidence for junctions (columns) across 481 TCGA lung
squamous cell carcinoma patients (rows) on an FPKM scale after log2(x + 1) transformation.
(C) Venn diagram illustrating mutual exclusive occurrence of NFE2L2 transcript alteration and mutation in KEAP1 or NFE2L2.
(D) Clustering of squamous NSCLC based on 27 candidate Nrf2 target genes. Mutation status and NFE2L2 transcript alteration are indicated for each sample.
(E and F) Venn diagram and clustering for head and neck cancers, otherwise as in (C) and (D).
See also Figure S2 and Table S3.of the identified splice variants. Out of 611 cell lines, we identified
one multiple myeloma cell line, KMS-27, and one hepatocellular
carcinoma cell line, JHH-6, both showing evidence for a hetero-
zygous skip of NFE2L2 exon 2 by junction reads (Figure 3A). We
validated the NFE2L2 exon 2 skipping by RT-PCR in JHH-6 and
KMS-27 mRNA. Using a series of forward and reverse primers
derived from exon 1 and from exons 3 and 4, we confirmed
the exon 2 deletion (De2 NFE2L2) in mRNA isolated from
JHH-6 and KMS-27 cells, respectively (Figure S3A). Sequencing
of the PCR products confirmed the expected deletion of exon 22608 Cell Reports 16, 2605–2617, September 6, 2016(Figure S3B). Based on RNA-seq data, we did not detect point
mutations in the coding sequence of NFE2L2 or KEAP1 in
JHH-6 or KMS-27 (Klijn et al., 2015; data not shown).
Given that Nrf2/KEAP1 alterations are common in hepato-
cellular carcinoma (10%) but infrequent in multiple myeloma
(0%) (http://www.cbioportal.org), we focused our attention on
JHH-6 cells. We asked whether the exon-2-deleted form of
Nrf2 protein (De2 Nrf2) was expressed in this line. We performed
western blotting of whole-cell lysates from JHH-6 cells, as
well as the KEAP1 mutant HUH-1 line, and from HuCCT1 as a
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Figure 3. Validation of Altered NFE2L2 mRNA and Nrf2 Protein in KMS-27 and JHH-6 Cell Lines
(A) RNA-seq data from KMS-27 and JHH-6 cells show presence of junction reads skipping exon 2. Read counts for each sample were scaled by a size factor
based on total read count for the sample divided by the median per-sample count. The bottom panel shows average scaled counts across 609 samples.
(B) Protein lysates from the indicated cell lines were separated by SDS-PAGE, and Nrf2 and actin were visualized by western blotting. The bands representing
wild-type Nrf2, phosphorylated Nrf2 (P-Nrf2), and exon-2-deleted Nrf2 (De2-Nrf2) are indicated. Asterisk represents a likely non-specific band, as it is not
depleted by Nrf2 siRNA (siNrf2).
(C) HuCCT1, JHH-6, or HUH-1 cells were grown in six-well dishes and then treated with 100 mg/ml cycloheximide (CHX) for the indicated times. The lysates were
incubated with either buffer or 400 U lambda phosphatase for 30min before separation by SDS-PAGE andwestern blotting with Nrf2 antibodies. Band intensities
of dephosphorylated full-length Nrf2 (for HuCCT1 and HUH-1 cells) or De2-Nrf2 (for JHH-6 cells) were then quantified and fitted to a one-phase decay curve.
(D) Cells were treated as in (C), except that they were transfected with either siNTC (50 nM) or siKEAP1 (50 nM) for 72 hr prior to harvest. Lysates were all treated
with 400 U lambda phosphatase for 30 min prior to separation by SDS-PAGE and western blotting with Nrf2 antibodies. Full-length Nrf2 (for HuCCT1 and HUH-1
cells) and De2-Nrf2 (for JHH-6 cells) were quantified and fitted to a one-phase decay curve.
See also Figure S3.representative wild-type KEAP1 liver cancer cell line. The levels
of Nrf2 in JHH-6 cells were comparable to those seen in HUH-1
cells, which were much higher than in the wild-type KEAP1
HuCCT1 cells (Figure 3B). Moreover, a species with smaller mo-
lecular weight, consistent with a deletion of exon 2, was detect-
able in JHH-6 and was reduced upon NFE2L2 small interfering
RNA (siRNA) transfection, confirming that it, indeed, represents
a form of Nrf2. We suspected that a phosphorylated form of
De2 Nrf2 might co-migrate with unphosphorylated wild-type
Nrf2 in the 4%–12% gels used. Indeed, dephosphorylation ofJHH-6 lysates confirmed that De2 Nrf2 was significantly more
abundant than the wild-type form (Figure 3C, middle panel).
Similarly, KMS-27 cells expressed De2 Nrf2, which was the ma-
jor species apparent upon dephosphorylation (Figure S3C).
We also analyzed the stability of Nrf2 in the three liver cancer
cell lines, using cycloheximide to halt total protein synthesis.
We used dephosphorylated lysates to allow more accurate
quantification of total Nrf2. The experiments showed increased
stability of De2 Nrf2 in JHH-6 cells, comparable to Nrf2 in
HUH-1 cells, which were both more stable than Nrf2 in HuCCT1Cell Reports 16, 2605–2617, September 6, 2016 2609
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Figure 4. Nrf2 Is Activated in Cell Lines Expressing Exon-2-Deleted NFE2L2
(A and B) Expression of 27 Nrf2/KEAP1 target genes in 16 hepatocellular carcinoma cell lines (A) and 18 multiple myeloma cell lines (B) using RNA-seq data
(described in Klijn et al., 2015; unpublished data). KMS-27 and JHH-6 are indicated as red open circles, and mutant KEAP1 liver cancer cell lines are indicated as
solid red circles.
(C and D) Bar graphs show the KEAP1 gene score (sum of Z scores for the 27 Nrf2/KEAP1 target genes determined over the full dataset) in the 16 hepatocellular
carcinoma cell lines (C) and 18 multiple myeloma cell lines (D). KEAP1 and NFE2L2 alterations are indicated as filled and outlined boxes, respectively.cells (Figure 3C). De2 Nrf2 in JHH-6 cells also showed prominent
nuclear localization (Figure S3D). Next, we asked whether the
deletion of exon 2 in JHH-6 cells made Nrf2 refractory to regula-
tion by KEAP1. Knockdown of KEAP1 in HuCCT1 cells resulted
in increased steady-state levels of Nrf2 due to increased stability
(Figure 3D). However, knockdown of KEAP1 in JHH-6 cells did
not affect the levels or stability of De2 Nrf2 (although the wild-
type form of Nrf2 in these cells showed increased stability). As
expected, knockdown of KEAP1 did not increase the stability
of wild-typeNrf2 in the KEAP1mutantHUH-1 cell line (Figure 3D).
KEAP1mRNA levels were equally decreased byKEAP1 siRNA in
all three cell lines (Figure S3E).
NFE2L2 Exon 2 Deletion Is Associated with Nrf2 Target
Gene Expression in Cell Lines
Using the Nrf2/KEAP1 gene signature on RNA-seq data from 16
hepatocellular carcinoma cell lines, we found that JHH-6 cells
show high expression of Nrf2 target genes, similar to cell lines
with KEAP1 mutations (Figure 4A). Similarly, analysis of 18 mul-
tiple myeloma cell lines demonstrated that KMS-27 cells show
high expression of these genes (Figure 4B). Expression of the2610 Cell Reports 16, 2605–2617, September 6, 201627 candidate target genes can be summarized by a ‘‘KEAP1
gene score,’’ calculated as the sum of Z scores for individual
target genes, with Z scores computed across the 611 cell lines
examined. This results in a single score per cell line that reflects
the extent of overexpression of signature genes. The KEAP1
gene score confirms that JHH-6 cells show a similar score as
KEAP1 mutant liver cancer cell lines (Figure 4C) and that KMS-
27 cells show the highest score among multiple myeloma cell
lines (Figure 4D), despite cell lines from this cancer showing a
low overall KEAP1 gene score.
Deletion of Exon 2 Results in Dependency on Nrf2
Next, we addressed whether JHH-6 cells expressing De2
NFE2L2 were more dependent on the expression of Nrf2 pro-
tein, compared to wild-type NFE2L2-expressing HuCCT1 cells.
Knockdown of NFE2L2 in JHH-6 cells caused a marked
decrease in cell viability, similar to that seen in the mutant
KEAP1 hepatocellular carcinoma cell line HUH-1. In contrast,
NFE2L2 knockdown had a more modest effect on the viability
of HuCCT1 cells (Figure 5A). This was not due to defective
NFE2L2 knockdown in HuCCT1 cells, as knockdown was
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Figure 5. Requirement for Exon-2-Deleted Nrf2 for Cell Viability
(A) HUH-1, JHH-6, and HuCCT1 cells were seeded into 96-well plates containing either non-targeted siRNAs (NTC) or siRNAs targeting Nrf2. Viability was
measured 4 days later using CellTiter-Glo. RLU, relative luminescence units.
(B) HUH-1, JHH-6, and HuCCT1 cells were grown in six-well dishes (Cells), treated with lipid agents only (lipid), and transfectedwith siRNAs against non-targeting
control (NTC) or NFE2L2 sequences (Nrf2). 48 hr later, total RNA was isolated, and expression of NFE2L2 was measured using Taqman probes.
(C) Cells were treated as in (B), but Taqman probes against the indicated Nrf2 target genes were used.NR0B1 expression was below detection levels in HuCCT1
cells.
(D) The indicated cell lines were reverse transfected with non-targeting control siRNA or NFE2L2 siRNA and were analyzed 96 hr later for propidium iodide (PI)
staining. The percent staining in the sub-G1 compartment is indicated. Staurosporine treatment (24 hr) was used as a positive control.
Error bars in (A)–(C) indicate mean ± SD (n = 3).equally efficient in all three cell lines (Figure 5B). Knockdown
of NFE2L2 also resulted in the decreased expression of four
Nrf2 target genes, although the effect was less pronounced in
the wild-type KEAP1 HuCCT1 cell line (Figure 5C). Decreased
viability was likely due, at least in part, to apoptosis, asmeasured
by an increase in fragmented DNA (Figure 5D).
Deletion of Exon 2 or Exon 2+3 Abolishes KEAP1
Interaction and Maintains Target Gene Expression
To address how loss of NFE2L2 exon 2 affects the ability of
Nrf2 to be regulated by KEAP1, we used transient expression
in 293 cells. KEAP1 decreased the expression of full-length
Nrf2 but had lesser effects on the expression of Nrf2 lacking
exon 2 or exon 2+3 (Figure 6A, upper panel). The inhibitory effect
of KEAP1 on full-length Nrf2 expression was mostly abolished
by the proteasome inhibitor MG132, as expected. Full-lengthNrf2 and KEAP1 interacted with each other, whereas deletion
of exon 2 or exon 2+3 completely abolished the ability of
KEAP1 to bind Nrf2 (Figure 6A, lower two panels). As a result
of this, altered Nrf2 remained stable following KEAP1 expres-
sion, in contrast to wild-type Nrf2 (Figure 6B), although the
altered forms of Nrf2 appeared to have slightly decreased
intrinsic stability. Altered Nrf2 isoforms were transcriptionally
active, as judged by their ability to increase Nrf2 target gene
expression (Figure 6C). Most genes were similarly increased
by De2 Nrf2 or De2+3 Nrf2, compared to full-length Nrf2, and
were resistant to the effects of KEAP1 overexpression. Inter-
estingly, De2+3 Nrf2 was defective for increasing GPX2 expres-
sion, suggesting that there might be subtle differences in the
transcriptional activation of this form of Nrf2. Consistent with
this observation, we also noticed that 21 of the 27 target
genes shown in Figure 1, as well as GPX2, showed lowerCell Reports 16, 2605–2617, September 6, 2016 2611
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Figure 6. Effect of NFE2L2 Exon 2 Deletion on Interaction with KEAP1
(A) 293 cells were transfected with plasmids expressing FLAG-Nrf2, De2 FLAG-Nrf2, De2,3 FLAG-Nrf2, or HA-KEAP1. 48 hr after transfection, cells were lysed,
and either whole-cell lysates (top gels) or anti-FLAG or HA immunoprecipitates (IPs) were analyzed by western blotting using the indicated antibodies.
(B) 293 cells were transfected with the same plasmids as described in (A) and then treated with 100 mg/ml cycloheximide (CHX) for the indicated times. Cells were
lysed and separated by SDS-PAGE and western blotted using Nrf2 and b-actin antibodies.
(C) Cells were treated as in (A) but harvested for total RNA, which was used to analyze the expression of the indicated genes using Taqman RT-PCR. Error bars
indicate mean ± SD (n = 3).
See also Figure S4.median expression in exon 2+3-deleted squamous lung tumors,
compared to exon 2-deleted tumors (p < 0.01, two-sided bino-
mial test; Figure S4).
NFE2L2 Transcript Variants Are Caused by Genomic
Alterations
Finally, we investigated the mechanism underlying the observed
NFE2L2 transcript alterations. Analysis of exome-seq data for
KMS-27 and JHH-6 showed a relative decrease in reads map-
ping to exon 2, suggesting that the observed transcript variants
could be the result of genomic alterations (Figure 7A). Indeed,
whole-genome sequencing of JHH-6 and KMS-27 showed that
these cell lines harbor microdeletions surrounding NFE2L2
exon 2, spanning 4,685 and 2,981 nt, respectively (Figure 7B;
Figure S5A). To investigate the causal mechanism in patients,
we analyzed comprehensive hybrid capture-based genomic
profiling data (Foundation Medicine) from a large cohort of clin-2612 Cell Reports 16, 2605–2617, September 6, 2016ical samples including different types of cancers (n = 58,707).
In this dataset, we identified 11 out of 1,218 squamous NSCLC
tumors that showed a decrease in copy number for exon 2 or
exon 2+3 compared to nearby control regions (Experimental
Procedures; Figure 7C). The focal nature of the deletions can
be appreciated by investigating log ratios from defined genomic
regions targeted for sequencing (Figure S5B). We also identified
seven squamous NSCLC tumors with discordant read pairs that
were consistent with structural variants encompassing several
kilobases of DNA and affecting exon 2 or exon 2+3 (Figure 7D).
In total, 16 out of 1,218 squamous NSCLC patients showed
evidence for genomic alterations affecting NFE2L2 exon 2 or
exon 2+3, and the identified events were mutually exclusive
with point mutations or indels in NFE2L2 and KEAP1, which
were observed in 171 patients and are known to activate this
pathway. Although we found a total of 45 cases with evidence
for genomic alterations in the complete cohort, squamous
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Figure 7. Genomic Microdeletions Underlie the Loss of NFE2L2 Exon 2
(A) Normalized exome-seq read counts for NFE2L2 exons across a panel of cancer cell lines (unpublished data). JHH-6 and KMS-27 are highlighted in green and
purple, respectively. Per-exon read counts were mean centered across exons and samples after log2(x + 1) transformation. E, exon.
(B) Heterozygous genomic deletions of NFE2L2 exon 2 identified by whole-genome sequencing of cell lines JHH-6 and KMS-27 and a lung tumor and adjacent
normal tissue.
(C) Normalized Z scores for exon read coverage across 1,218 squamous NSCLC tumors. Tumors with identified exon 2 deletion or exon 2+3 deletion are
highlighted in red and blue, respectively. Z scores were mean centered across exons for each sample.
(D) Genomic location of structural variants affecting NFE2L2 exon 2 or exon 2+3 identified based on discordant read pairs. Asterisk indicates an inversion.
See also Figures S5 and S6.NSCLC was the only cancer type that showed a statistically
significant enrichment (adjusted p = 3 3 1014, two-sided
Fisher’s exact test). We note that our ability to detect structural
variants in this dataset is limited. Identification of heterozygous
deletions is challenging due to variability in read coverage, while
breakpoints for structural variants are only identified if they are
located in close proximity to a genomic region targeted for
sequencing. Therefore, we analyzed an additional cohort of 45
squamous NSCLC tumors for which both RNA and DNA were
available. RT-PCR analysis identified a single patient with loss
of exon 2, which was strongly enriched in the tumor compared
to adjacent normal tissue (Figure S6A). RNA-seq analysis
confirmed that the transcript variant was expressed in the
identified tumor but was absent in adjacent normal tissue
(Figure S6B). Expression of Nrf2 target genes was elevated
to a similar extent as in TCGA tumors with known mutations in
the pathway, whereas the adjacent normal tissue showed low
target gene expression (Figure S6C). Finally, whole-genome
sequencing confirmed that the transcript variant was the resultof a somatic genomic microdeletion of 5,233 nucleotides sur-
rounding exon 2 (Figure 7B; Figure S5A). These data suggest
that genomic microdeletions are a clinically relevant mechanism
for Nrf2 pathway activation.
DISCUSSION
Genomic analysis of a large panel of lung cancer cell lines (Klijn
et al., 2015; data not shown) allowed us to identify genes that are
differentially expressed in KEAP1mutant compared to wild-type
cell lines. All but one of the genes identified showed increased
expression, consistent with the evidence that the KEAP1 target
Nrf2 is a positive regulator of gene transcription. Fifteen of the
27 genes had been previously identified as Nrf2 target genes
from ChIP-seq and RNA-seq experiments in cells from different
tissues and species (Chorley et al., 2012; Hirotsu et al., 2012;
Malhotra et al., 2010), and a further 8 were identified as showing
similar expression to ‘‘classic’’ Nrf2 target genes (DeNicola et al.,
2015) or upregulated upon KEAP1 knockdown in keratinocytesCell Reports 16, 2605–2617, September 6, 2016 2613
(MacLeod et al., 2009), implying that the set of genes regulated
by Nrf2 is highly conserved across different tissues and condi-
tions. This has practical value in the use of a single gene signa-
ture to identify tumors with Nrf2 activation in both NSCLC and
HNSC (Figure S6D). Interestingly, the Nrf2/KEAP1 signature is
only activated in tumors. Matched normal samples for lung and
for head and neck tumors showed only low Nrf2 target gene
activity (Figure S6E), suggesting that inhibition of the pathway
might have selective benefit in tumors showing pathway dereg-
ulation compared to normal tissues.
Intragenic genomic deletions that result in activation of
proto-oncogenes have previously been reported for a number
of genes, including EGFR and CTNNB1. Such variants are not
routinely assayed, which is due, in part, to the limitations of
current genomic technologies. Alterations affecting individual
exons and involving small copy-number changes are difficult to
detect by exome-seq. Therefore, intragenic deletions have re-
mained relatively unexplored, and new variants are still being
discovered. Recent studies of small-cell lung cancer and adult
T cell leukemia/lymphoma identified recurrent microdeletions
in TP73, IKZF2, and CARD11 using whole-genome sequencing
(George et al., 2015; Kataoka et al., 2015). Here, we used publicly
available RNA-seq data generated as part of the TCGA project
to identify recurrent transcript alterations in known oncogenes.
Due to differences between patient cohorts, it is difficult to
accurately assess the general prevalence of NFE2L2 exon dele-
tions. When analyzing TCGA lung squamous cell cancers with
available RNA-seq data (n = 481), we identified 3% (16/481) of
patients with the deletion of NFE2L2 exon 2 or exon 2+3.
When analyzing the subset of patients with available exome-
seq data (n = 178), for which somatic mutation calling can be
performed, the proportion of patients with NFE2L2 exon dele-
tions was 6% (10/178). Thus, accounting for NFE2L2 exon dele-
tions increased the percentage of patients with putative Nrf2
pathway activation from 27% (48/178) to 33% (58/178) in lung
squamous carcinoma and from 9% (26/275) to 11% (31/275) in
head and neck squamous carcinoma, compared to assessing
mutations in NFE2L2 or KEAP1 by exome-seq alone (Figures
2C and 2E). Analysis of real-world clinical samples from patients
that underwent genomic profiling suggested a prevalence of
NFE2L2 exon deletions in 1%–2% of lung squamous cell carci-
noma. However, the latter analysis lacks sensitivity, since only
unambiguous deletions were considered. In the future, more
comprehensive screening of known cancer genes may be
achievable through the sequencing of complete gene loci,
including introns, or by combining data from exome-seq and
RNA-seq experiments.
We confirmed deletions of NFE2L2 exon 2 at the genomic,
transcript, and protein levels using cell-line models JHH-6 and
KMS-27. Cell-line studies further demonstrated that deletion
of NFE2L2 exon 2 or exon 2+3 results in the loss of interac-
tion with KEAP1, Nrf2 stabilization, induction of a Nrf2 transcrip-
tional response, and Nrf2 pathway dependence. However, we
acknowledge that these results were obtained in the specific
cellular and genetic context of the cell lines used in this study.
Interestingly, even in cell lines with mutations in KEAP1 or
NFE2L2, Nrf2 protein levels are still unstable. Nrf2 stability is likely
regulated by additional factors; for example, b-TrCP (Chowdhry2614 Cell Reports 16, 2605–2617, September 6, 2016et al., 2013) and/or SIAH2 (Baba et al., 2013). Differing levels
of these or other E3 ligase adaptors could explain residual
Nrf2 instability, as well as differences in Nrf2 stability between
JHH-6 and HUH-1 cells.
Deletion of exon 2 provides an elegant mechanism to increase
Nrf2 activity by removing the interaction site with KEAP1 while
keeping the remainder of the gene functionally intact. Indeed,
biochemical analyses confirmed an almost complete loss of
KEAP1 binding and stabilization of Nrf2 when exon 2 is deleted
(Figures 6A and 6B). When considering NFE2L2 point muta-
tions found in tumors, mutations surrounding the ETGE high-af-
finity binding site result in complete loss of KEAP1 interaction,
whereas mutations in the lower affinity DLG motif vary in their
ability to disrupt the Nrf2/KEAP1 complex (Fukutomi et al.,
2014; Shibata et al., 2008). However, even point mutations
that do not disrupt the complex change the nature of the inter-
action so as to prevent KEAP1-mediated ubiquitination of
Nrf2 (Shibata et al., 2008). While the interaction with KEAP1 is
similarly abolished in the case of deletion of exon 2+3, exon 3
contains the Neh4 domain that has been previously implicated
in transcriptional activation by Nrf2 through binding to CBP
(CREB [cAMP response element-binding protein]-binding pro-
tein) (Katoh et al., 2001). Neh4 (exon 3) and Neh5 (exon 4)
were shown to act synergistically in recruiting CBP. The Neh4
and Neh5 domains of Nrf2 have also been shown to be impor-
tant for binding the Mediator complex (Sekine et al., 2015) and
the SWI/SNF component BRG1 (Zhang et al., 2006), demon-
strating the importance of these domains in Nrf2 transcriptional
activation. Consistent with this, we observe decreased ability of
De2+3 Nrf2 to induce some Nrf2 target genes compared to De2
Nrf2 or point mutations in NFE2L2 (Figure 6C; Figure S4). How-
ever, recurrence of De2+3 Nrf2 suggests that it is selected
in the evolution of lung tumors. It will be interesting to define
more precisely the transcriptional profile of this Nrf2 isoform to
help inform the specific subset of genes that are required for
the tumorigenic properties of Nrf2 in lung cancer. It might also
be interesting to test any emerging CBP inhibitors for their ability
to inhibit GPX2 and other Nrf2 target genes in KEAP1/Nrf2
mutant tumors.
Deletions found in human tumors that remove the interaction
domain with E3 ligases have also been seen in other genes.
For example, 7 out of 222 colorectal tumors showed small
genomic deletions surrounding exon 3 of b-catenin (Iwao et al.,
1998) that remove the interaction site for its E3 ligase b-TrCP
(Hart et al., 1999). Similarly, the majority of TMPRSS-ERG and
TMPRSS-ETV1 fusion proteins found in prostate cancer encode
truncated versions of transcription factors that render them
resistant to ubiquitination and degradation mediated by SPOP
or COP1, respectively (An et al., 2015; Vitari et al., 2011). In
addition, mutations resulting in MET exon 14 skipping remove
amino acid residue Y1003, which is required for Cbl recruitment
and subsequent ubiquitination and downregulation. Therefore,
small intragenic deletions represent effective mechanisms for
nascent oncogenes to escape normal degradation during tumor
initiation and evolution. This suggests that increased use of both
whole-genome sequencing and integrative analysis with RNA-
seq will help identify oncogenes activated by this and other
mechanisms.
EXPERIMENTAL PROCEDURES
TCGA and GTEx Data
TCGA RNA-seq data were obtained from the Cancer Genomics Hub at
the University of California, Santa Cruz. Raw FASTQ files were downloaded
in batches as they became available. For samples without available
FASTQ files, BAM files were converted to FASTQ. The latest TCGA down-
loads were based on a manifest created on July 14, 2015. Mutation and
copy-number data were retrieved from cBioPortal (http://www.cbioportal.
org), using the R software package CGDS-R (Cerami et al., 2012; Gao
et al., 2013). Raw FASTQ files for GTEx RNA-seq data were downloaded
from dbGaP (http://www.ncbi.nlm.nih.gov/gap) using accession code
phs000424.v4.p1.
RNA-Seq Analysis
RNA-seq data were aligned to the human reference genome (GRCh37/hg19)
using GSNAP version 2013-10-10 (Wu and Nacu, 2010) (parameters: -M 2 -n
10 -B 2 -i 1 -N 1 -w 200000 -E 1 --pairmax-rna=200000 --clip-overlap).
Gene expression levels for RefSeq genes were quantified based on counts
and RPKM (reads per kilobase of target and million reads sequenced) values.
Derivation of a Mutant KEAP1 Gene Expression Signature
RNA-seq data for 99 NSCLC cell lines (Table S1) were retrieved from the
European Genome-phenome Archive: EGAS00001000610 (Klijn et al., 2015).
Using the DESeq R package (Anders and Huber, 2010) we measured differen-
tial gene expression between KEAP1 mutant (point mutation or genomic
deletion) and wild-type cell lines, reported as fold change and associated
adjusted p values. Signature genes were selected based on an adjusted
p <0.01 and mean log2 fold change >1. For ward clustering of samples and
genes (using Euclidean distance) variance-stabilized count data were used.
The NMF (Non-negative Matrix Factorization) R package was used to create
associated heatmaps. The KEAP1 gene score was computed as the sum of
Z scores for 27 signature genes based on read counts after voom transforma-
tion (Law et al., 2014).
Splice Variant Analysis
Analysis of splice variants was performed using the R/Bioconductor package
SGSeq (version 1.3.14) (Goldstein et al., 2016). We predicted exons and splice
junctions from BAM files for 7,384 TCGA samples (parameters: alpha = 2,
psi = 0, beta = 0.2, and gamma = 0.2) at 54 genomic loci of known oncogenes
(Vogelstein et al., 2013). Predictions were merged across samples and assem-
bled into a splice graph. Splice events consisting of two or more alternative
splice variants were identified from the graph. Evidence for splice variants
was quantified in terms of FPKM (fragments per kilobase andmillion fragments
mapped) and estimates of relative usage. Relative usage estimates with a
denominator less than 20 were set to NA. Splice variants detected in TCGA
samples were also quantified in 2,958 GTEx samples from normal human
tissues (GTEx Consortium, 2015).
Identification of Cancer-Specific Splice Variants
We considered internal splice variants (not involving alternative transcript
starts or ends) and required the start and end of each splice variant to either
overlap or extend exons that belong to annotated RefSeq transcripts down-
loaded from the UCSC (University of California, Santa Cruz) Genome
Browser website (Pruitt et al., 2005; Rosenbloom et al., 2015). Retained
introns were excluded. We considered 19 TCGA cancer types that included
samples from at least 100 patients (6,359 cancer samples in total) and
selected splice variants with (1) an FPKM >2 and estimated relative
usage >0.2 in at least one cancer sample, (2) an FPKM <1 in > 99.9% of
GTEx samples, and (3) an FPKM of 0 in >97.5% of GTEx samples. FPKM-
based criteria were required to be satisfied at both the start and the end
of the splice variant. Variants satisfying the FPKM-based criteria for which
relative usage could not be estimated were included after manual inspec-
tion. Filtering for recurrence (> 1%, n R 3 for a given cancer type) resulted
in nine variants, each corresponding to a single exon-exon junction. In
subsequent analyses, these variants were considered present in samples
with an FPKM >2 (Table S3).Analysis of the FoundationCORE Comprehensive Genomic Profiling
Database
Samples were processed and sequenced similarly as previously described
(Frampton et al., 2013). We screened the November 2015 data freeze of Foun-
dationCORE (n = 58,707) for NFE2L2 exon 2 or exon 2+3 deletions using two
approaches. First, rearrangement calls based on discordant read pairs and/or
split reads were examined for the loss of NFE2L2 exon 2 or exon 2+3. Since
intronic regions of NFE2L2 are not captured, this approach is limited to the
identification of deletions in which breakpoints occur near intron-exon bound-
aries or within exons. The second approach uses copy-number log ratios
for individual bait regions. Copy-number log ratios were determined with an
in-house algorithm educated to the specific tumor cellularity of each sample.
A Z score was calculated comparing the log ratio for each exon in NFE2L2
to control polymorphism capture regions immediately adjacent to NFE2L2
(n = 15; evenly spaced every1MB from3MBupstream and12MB down-
stream of NFE2L2). Exon 2 deletions with and without a concurrent exon 3
deletion were identified (for simplicity, referred to as ‘‘exons of interest,’’ or
EOIs). EOI deletions were called if (1) Z scores were less than 2 for EOIs
and not for non-EOIs in NFE2L2 and (2) there was a log-ratio drop of 0.2
from non-EOIs in NFE2L2. To investigate whether specific cancer types
were associated with genomic alterations in NFE2L2 exon 2 or exon 2+3
(detected by copy-number log ratio or discordant read pairs), we considered
85 cancer types with at least 100 patients. For each cancer type, we used a
two-sided Fisher’s exact test to assess whether cases were enriched or
depleted compared to the rest of the dataset. The p values were adjusted
for multiple testing using the Benjamini-Hochberg method.
Cell Culture
KMS-27 (RPMI-1640), JHH-6 (Williams Media E), HuCCT1 (RPMI-1640), and
HUH-1 (DMEM) cells were from JCRB (Japanese Collection of Research Bio-
resourcesCell Bank), and 293 (Eagle’sminimal essential medium; EMEM) cells
were from ATCC; they were cultured in the indicated media in the presence of
2 mM glutamine and 10% fetal bovine serum (FBS).
Western Blotting
Cell lysates were prepared with RIPA Buffer (Sigma) supplemented with com-
plete EDTA-free protease inhibitor (Roche) and phoSTOP (Roche), Phospha-
tase Inhibitor Cocktail 2 (Sigma), and Phosphatase Inhibitor Cocktail 3 (Sigma).
Lysates were run on Novex Tris-Glycine 4%–12% gradient gels (Thermo-
Fisher) and then transferred onto iBlot nitrocellulose (Invitrogen). Blots
were pre-incubated in 5% skim milk powder (Merck) in Tris-buffered saline
with Tween 20 (TBST; 10 mM Tris [pH 8], 150 mM NaCl, 0.1% Tween 20),
followed by 5% BSA (Sigma) in TBST containing antibodies. Secondary anti-
bodies used were ECL Anti-Rabbit HRP (horseradish peroxidase) and ECL
Anti-Mouse HRP (both from GE Healthcare). Blots were developed with the
ChemiGlow Chemiluminescence Substrate Kit (Protein Simple) and visualized
with a FluorChem HD2 imager (Protein Simple). Antibodies used in this study
are against KEAP1 (Cell Signaling, G1D10), Nrf2 (Abcam, ab62352), HSP90
(Cell Signaling, 4877), HDAC2 (Cell Signaling, 5113), b-actin (Sigma, A2228),
hemagglutinin (HA; Roche, 11815016001), FLAG (Sigma, F2426). Lambda
phosphatase was from New England Biolabs (P0753L), and phosphatase
inhibitors were omitted from the lysis buffer in these experiments.
Cell Viability and DNA Fragmentation Analysis
siRNAs were reverse transfected into cells with Dharmafect 2 reagent
(ThermoFisher) and Opti-MEM (GIBCO). Four days post-transfection, cells
were measured for viability using CellTiter-Glo reagent (Promega), and
luminescence was detected on an EnVision Multilabel Reader (PerkinElmer).
Four days post-transfection, cells were measured for apoptosis using
propidium iodide (LifeTechnologies) staining and flow cytometry following a
published protocol (Riccardi and Nicoletti, 2006). Staurosporine (1 mM;
Enzo Life Sciences) was added to positive control cells 24 hr pre-staining.
NFE2L2 siRNAs were: 50-TGACAGAAGTTGACAATTA-30 and 50-GTAAGAAG
CCAGATGTTAA-30 and were used along with siGENOME Non-Targeting
siRNA Pool #2 (GE Healthcare) as control siRNA. Stained cells were analyzed
with a Becton Dickinson FACSCaliber instrument. siRNAs targeting KEAP1
were from Dharmacon (L012453-00).Cell Reports 16, 2605–2617, September 6, 2016 2615
Taqman Analysis
Total cellular RNA was extracted with an RNeasy Kit (QIAGEN). RNA was con-
verted to cDNA using a cDNA Reverse Transcription Kit (Applied Biosystems),
and cDNAs were amplified with Taqman Gene Expression primer-probe
sets (ThermoFisher), using Taqman Gene Expression Master Mix reagents
(Applied Biosystems). Taqman amplification/detection was performed on
the QuantStudio7 Flex Real-Time PCR System. The Hs00975961_g1
primer-probe set was used to detect NFE2L2 (ThermoFisher). The Nrf2
target gene Taqman primer-probe sets used were as follows: SLC7A11
(Hs00921938_m1), SGRN (Hs00921938_m1), NR0B1 (Hs03043658_m1),
GCLC (Hs00155249_m1),GPX2 (Hs01591589_m1), andKEAP1 (Hs00202227_
m1), all from ThermoFisher.
293 Transfections
Target DNAs in pRK5 were transfected into cells using Lipofectamine 2000
(ThermoFisher) and Opti-MEM (GIBCO) as recommended by manufacturer’s
protocol.
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